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Abstract
We reported an association between elevated vancomycin MIC and 30-day mortality in patients with Staphylococcus aureus bacteraemia
(SAB), including patients with methicillin-susceptible S. aureus (MSSA) treated with ﬂucloxacillin. A detailed analysis of comorbidities and
disease severity scores in the same cohort of patients was performed to ascertain if unknown clinical parameters may have inﬂuenced these
results. The association between elevated vancomycin MIC and 30-day mortality in SAB remained signiﬁcant (p 0.001) on multivariable
logistic regression analysis even when accounting for clinical factors. In addition, the association persisted when restricting analysis to
patients with MSSA bacteraemia treated with ﬂucloxacillin. This suggests that elevated vancomycin MIC is associated with but not causally
linked to an organism factor that is responsible for increased mortality.
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Background
In a previous study we demonstrated an association between
elevated vancomycin MIC and 30-day all-cause mortality in a
large cohort of patients with Staphylococcus aureus bacteraemia
(SAB) in Australia and New Zealand that was independent of the
methicillin susceptibility of the blood culture isolate or antibiotic
treatment received [1]. However, it is uncertain whether this
association was confounded by clinical parameters not available
at the time of our initial publication. Elevated vancomycin MIC
within the susceptible range has not been uniformly associated
with poor outcome [2], and differing comorbidities may
potentially explain this observation. Therefore we chose to
search for potential hidden clinical confounders in our cohort of
patients to determine whether we could explain differences that
we had previously observed in 30-day survival.
Materials and Methods
Study population
The study population was derived from our previously
described cohort of adult and paediatric patients hospitalized
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with SAB in Australia and New Zealand at eight sites [1].
Patients were divided into two groups according to whether
their initial S. aureus blood culture isolate had a low or
elevated vancomycin MIC within the susceptible range, deﬁned
as Etest  1.5 mg/L or >1.5 mg/L, respectively. The main
outcome measure was 30-day all-cause mortality from the date
of the ﬁrst positive (index) blood culture. We also analysed
30-day attributable mortality as deﬁned by Lodise et al. [3].
Data collection
Extensive clinical data were collected retrospectively using
chart review: heart disease (including ischaemic heart disease,
cardiac failure, arrhythmia requiring insertion of permanent
pacemaker or implantable cardioverter-deﬁbrillator), end--
stage kidney disease, receipt of haemodialysis, diabetes mell-
itus, dementia, chronic liver disease, malignancy
(haematological or solid organ), transplantation (haematolog-
ical or solid organ), receipt of chemotherapy, immunosup-
pression or corticosteroids (with an equivalent daily dose of
 20 mg prednisone), human immunodeﬁciency virus infec-
tion and active injecting drug use were assessed as individual
comorbidities. We assessed comorbidity burden using the
Charlson Comorbidity Index (CCI) [4] and presence of ‘Do
Not Resuscitate’ (DNR) orders. Disease severity at onset of
SAB was measured using intensive care unit (ICU) -validated
scores: Acute Physiology And Chronic Health Evaluation
(APACHE) II, Simpliﬁed Acute Physiology Score (SAPS) II and
the Pitt bacteraemia score [5], a bacteraemia-validated
method. Other data obtained included ICU admission and
renal function at SAB onset. For data analysis, dichotomous
variables for CCI and disease severity scores were also
created using values associated with inferior outcomes in the
published literature (APACHE II  18 [6], SAPS II >45 [7], CCI
 3 [4], Pitt bacteraemia score  4 [8]).
Microbiological data
The index blood culture isolate from each patient was stored
at 80°C and underwent detailed microbiological testing as
previously described [1]. Brieﬂy, this included vancomycin MIC
using broth microdilution [9] and Etest (bioMerieux, Marcy
l’Etoile, France) methodologies, and screening for vancomycin
heteroresistance was performed using the Glycopeptide
Resistance Detection Etest (bioMerieux, Marcy l’Etoile,
France).
Statistical analysis
The chi-square test or Fisher exact test was used to compare
categorical variables, and the Student’s t-test or Mann–
Whitney U test was used for continuous variables. Potentially
signiﬁcant variables on univariable analysis (p <0.2) were
considered a priori for inclusion in a multivariable logistic
regression model. Pairwise correlation coefﬁcients were exam-
ined between variables that were potentially related before
inclusion in our multivariable model to avoid collinearity.
Stepwise backward elimination was performed and variables
with p <0.05 were retained in the ﬁnal multivariable model. The
Hosmer–Lemeshow statistic was performed to test the good-
ness of ﬁt of the ﬁnal model. A p-value of <0.05 was considered
statistically signiﬁcant, and analysis was performed using STATA
v11.1 (StataCorp, College Station, TX, USA).
Ethics
Human ethics committee approval was obtained at each of the
participating sites.
Results
Demographics
Expanded clinical data were available for 418 patients from our
original cohort (78.6%), with 30-day mortality data available in
410 patients. Demographics, comorbidities and disease severity
scores are summarized in Table 1 according to vancomycinMIC
group (low versus elevated but within the susceptible range) and
30-day mortality. Overall the mean age ( SD) of our patients
was 57.8  21.4 years. The median duration of bacteraemia
was 1 day (interquartile range 1–2 days). DNR orders were
documented in 101/373 (27.1%) patients, more than a third of
which were recorded before a diagnosis of SAB (38/101, 37.6%).
Attributable 30-day mortality was 10.7% (44/410) compared
with all-cause mortality (18.0%, 74/410), and elevated vanco-
mycinMICwas statistically associatedwith both attributable and
all-cause mortality (p <0.001 and p 0.002, respectively).
Patients with elevated vancomycin MIC were more likely to
have hospital onset bacteraemia, to have infection with
methicillin-resistant S. aureus (MRSA), to receive treatment
with vancomycin and to have higher mortality. At 30 days,
non-survivors were older and more likely to experience
hospital-onset bacteraemia, ICU admission, sepsis syndrome
and have an isolate with an elevated vancomycin MIC.
Effect of individual comorbidities
The presence of heart disease (as deﬁned above), diabetes
mellitus, end-stage kidney disease and malignancy was common
in our cohort (34.2%, 26.3%, 16.0%, 20.1%, respectively;
Table 1). Malignancy was associated with both elevated
vancomycin MIC (p 0.009) and 30-day mortality (p 0.037)
but not 30-day attributable mortality (p 0.428). Heart disease
was associated with mortality (p 0.001) but not elevated
vancomycin MIC.
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Effect of comorbidity burden
Patients with elevated vancomycin MIC had a higher number of
comorbidities (speciﬁcally CCI  3 and DNR orders, Table 1),
suggesting that multiple comorbidity burden may be a potential
confounder inﬂuencing the observed association between
increased vancomycin MIC and mortality. As expected, high
comorbidity burden was associated with increased mortality.
Effect of disease severity scores
Disease severity score measures were similar in the low and
elevated vancomycin MIC groups using both ICU and bacter-
aemia scores at onset of SAB, although there was a tendency
towards higher APACHE II and SAPS II scores with elevated
vancomycin MIC. As expected, all disease severity scores were
higher in non-survivors, either using the raw numerical score
or the dichotomized category.
Factors associated with 30-day mortality
To determine how these comorbidity variables impacted on
the association between elevated vancomycin MIC and mor-
tality, we used a multivariable logistic regression model. We
considered including variables with univariate p <0.2 for
multivariable analysis; however, we only selected variables
with univariate p <0.05 for inclusion into our logistic regres-
sion model because of sample size considerations (Table 2). In
addition, variables that were correlated were not entered
TABLE 1. Demographics, comorbidities and disease severity scores for 418 patients with Staphylococcus aureus bacteraemia
Variable
Vancomycin MIC group (n = 418)
p value
30-day outcome (n = 410)
p valueLowa (n = 280) Elevateda (n = 138) Alive (n = 336) Dead (n = 74)
Demographics
Age  70 years 94 (33.6) 54 (39.1) 0.278 101 (30.1) 45 (60.8) <0.001
Age <18 years 11 (3.9) 6 (4.4) 0.798 15 (4.5) 1 (1.4) 0.324
Male sex 198 (70.7) 93 (67.4) 0.499 233 (69.4) 52 (70.3) 1.000
Hospital onset 105 (37.5) 75 (54.4) 0.001 136 (40.5) 41 (55.4) 0.020
Methicillin-resistant S. aureus 77 (27.5) 70 (50.7) <0.001 112 (33.3) 33 (44.6) 0.081
Device-associated 114/262 (43.5) 67/133 (50.4) 0.202 149/319 (46.7) 29/69 (42.0) 0.508
Intensive care unit admission 79/278 (28.4) 41/136 (30.2) 0.730 87/332 (26.2) 31/74 (41.9) 0.010
Acute renal failure 60/276 (21.7) 37/137 (26.3) 0.323 72/331 (21.8) 24/74 (32.4) 0.069
Principal clinical manifestation
Infective endocarditis 29 (10.4) 8 (5.8) 0.145 32 (9.5) 4 (5.4) 0.364
Osteoarticular 29 (10.4) 11 (8.0) 0.484 33 (9.8) 6 (8.1) 0.827
Skin and skin structure 37 (13.2) 24 (17.4) 0.302 49 (14.6) 9 (12.2) 0.713
Sepsis syndrome 23 (8.2) 18 (13.0) 0.161 24 (7.1) 17 (23.0) <0.001
Pneumonia 15 (5.4) 8 (5.8) 0.823 17 (5.1) 6 (8.1) 0.276
Vancomycin treatment 108 (38.6) 79 (57.3) <0.001 148 (44.1) 38 (51.4) 0.302
Outcomes
Elevated vancomycin MICa NA NA NA 96 (28.6) 39 (52.7) <0.001
30-day all-cause mortality 35/275 (12.7) 39/135 (28.9) <0.001 NA NA NA
30-day attributable mortality 20/275 (7.8) 24/135 (17.8) 0.002 NA NA NA
Persistent bacteraemiab 17/216 (7.9) 8/115 (7.0) 0.831 18/269 (7.0) 7/56 (12.5) 0.165
Recurrent bacteraemiac 20/269 (7.4) 9/133 (6.8) 1.000 25/328 (7.6) 4/71 (5.6) 0.801
Comorbidities
Heart disease 95 (33.9) 48 (34.8) 0.913 102 (30.4) 38 (51.4) 0.001
Diabetes mellitus 76 (27.1) 34 (24.6) 0.637 90 (26.8) 20 (27.0) 1.000
End-stage kidney disease 45 (16.1) 22 (15.9) 1.000 59 (17.6) 8 (10.8) 0.169
Haemodialysis 39/279 (14.0) 21/136 (15.4) 0.766 53 (15.8) 7 (9.5) 0.204
Dementia 13 (4.6) 4 (2.9) 0.599 13 (3.9) 4 (5.4) 0.523
Chronic liver disease 34 (12.1) 13 (9.4) 0.511 33 (9.8) 11 (14.9) 0.215
Malignancy 46 (16.4) 38 (27.5) 0.009 61 (18.2) 22 (29.7) 0.037
Transplantation 11 (3.9) 6 (4.3) 0.798 17 (5.1) 0 (0.0) 0.051
Immunosuppression 35 (12.5) 21 (15.2) 0.448 50 (14.9) 6 (8.1) 0.138
HIV infection 3 (1.1) 1 (0.7) 1.000 4 (1.2) 0 (0.0) 1.000
Active injecting drug use 21 (7.5) 5 (3.6) 0.137 25 (7.4) 0 (0.0) 0.012
Comorbidity burden
CCI
Mean  SD 1.6  1.5 2.0  1.7 0.015 1.6  1.5 2.3  1.7 0.003
Score  3 [4] 72 (25.7) 51 (37.0) 0.022 93 (27.7) 29 (39.2) 0.067
DNR order 50/248 (20.2) 51/125 (40.8) <0.001 41/291 (14.1) 60/74 (81.1) <0.001
Disease severity scores
APACHE II
Mean  SD 14.2  6.6 15.4  6.8 0.084 13.6  6.4 19.3  6.2 <0.001
Score  18 [6] 79 (28.2) 50 (36.2) 0.115 90 (26.8) 39 (52.7) <0.001
SAPS II
Mean  SD 25.4  10.9 28.0  12.5 0.030 24.4  10.7 35.4  10.8 <0.001
Score >45 [7] 18 (6.4) 12 (7.6) 0.423 20 (6.0) 10 (13.5) 0.044
Pitt bacteraemia score
Mean  SD 2.6  1.8 2.8  1.9 0.295 2.5  1.7 3.4  2.3 <0.001
Score  4 [8] 56 (20.0) 33 (23.9) 0.375 59 (17.6) 29 (39.2) <0.001
Data are expressed as number (%) unless otherwise speciﬁed.
p value calculated using Fisher’s exact test or Student’s t-test where appropriate.
APACHE, Acute Physiology And Chronic Health Evaluation; CCI, Charlson Comorbidity Index; DNR, Do Not Resuscitate; HIV, human immunodeﬁciency; virus; NA, not assessed;
SAPS, Simpliﬁed Acute Physiology Score; SD, standard deviation.
aElevated vancomycin MIC deﬁned as Etest >1.5 mg/L.
bDeﬁned as positive blood culture for SAB 7 days or more after index blood culture.
cDeﬁned as new positive SAB within 30 days of index blood culture after documentation of negative blood cultures.
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twice in the model. For example, age is a component of the
APACHE II and the SAPS II scores and so these variables were
not included together. In contrast, age is not required for
calculation of the Pitt bacteraemia score so both these
variables could be considered. Speciﬁc comorbidities such as
heart disease and malignancy are components of the CCI.
Although DNR orders were strongly associated with mortal-
ity, we did not consider this variable for inclusion in our
multivariable model because DNR orders result in treatment
modiﬁcation or complete cessation that directly impacts on
patient outcome. Using backward stepwise elimination, param-
eters that were signiﬁcantly associated with 30-day mortality
were age  70 years, sepsis syndrome, elevated vancomycin
MIC and Pitt bacteraemia score  4 (Table 2). That is, even
when adjusting for these potential clinical confounders, our
original association between elevated vancomycin MIC and
mortality in SAB still remained signiﬁcant. The ﬁnal logistic
regression model appeared robust (Hosmer–Lemeshow sta-
tistic, p 0.981). When we substituted age  70 years with an
acute physiology score (either APACHE II or SAPS II), elevated
vancomycin MIC remained signiﬁcant in the ﬁnal model (data
not shown). When we included DNR orders in our multivar-
iable analysis for 30-day mortality, only sepsis syndrome
(p <0.001) and DNR orders (p <0.001) were signiﬁcant in the
ﬁnal model. DNR orders were more strongly correlated with
30-day mortality (Spearman r = 0.602) than elevated vanco-
mycin MIC (Spearman r = 0.219).
Thirty-day attributable mortality (instead of all-cause
mortality) was associated with elevated vancomycin MIC as
well as age  70 years and sepsis syndrome in a similar
multivariable logistic regression model (p 0.007, p 0.005,
p 0.034, respectively); a Pitt bacteraemia score  4 did not
achieve statistical signiﬁcance (p 0.053). When we restricted
the multivariable analysis to the sub-group of patients with
methicillin-susceptible S. aureus (MSSA) bacteraemia who were
treated with ﬂucloxacillin, the association between elevated
vancomycin MIC and mortality persisted (p 0.001); age
 70 years and sepsis syndrome were also signiﬁcant in the
model (p <0.001 and p 0.019 respectively).
Discussion
We have previously reported that in patients with SAB,
elevated vancomcyin MIC within the susceptible range is
associated with increased 30-day mortality. This ﬁnding
remained signiﬁcant even in the subgroup of patients with
SAB due to MSSA who received ﬂucloxacillin treatment,
suggesting that vancomycin MIC is a marker of host or
pathogen determinants rather than being causally associated
with poor outcome. Here, we have enriched our cohort by
including a range of new clinical data to examine whether host
factors may have explained the difference in mortality that we
initially observed.
Subtle elevations in the vancomycin MIC within the
susceptible range have been increasingly linked to mortality
and other inferior outcomes in SAB [2,10]. This ﬁnding,
however, is not consistent among all publications [11].
Differences in MIC methodology and MIC values [2] associated
with these poor outcomes, as well as the potential impact of
the timing of isolate testing [12], make clinical interpretation
and application difﬁcult. Recent MRSA treatment consensus
guidelines suggest that a patient’s clinical and microbiological
response should guide clinicians about continuing vancomycin
treatment, rather than a speciﬁc vancomycin MIC result [13].
Vancomycin susceptibility is undoubtedly important in treat-
ment outcome when strains are intermediate or resistant
(broth microdilution MIC >2 mg/L), and it is difﬁcult to achieve
target pharmacokinetic–pharmacodynamic measures in vanco-
mycin-treated patients using recommended dosing regimens
when the vancomycin MIC is  2 mg/L [14].
We found that the inclusion of a range of additional
comorbid conditions generally had little impact on outcome.
Measures of comorbidity burden, such as the CCI, or speciﬁc
individual comorbidities, such as malignancy, were linked to
vancomycin MIC and outcome on univariable analysis but failed
to remain signiﬁcant in the ﬁnal multivariable model. As
expected, disease severity scores were strongly associated
with mortality. Yet despite considering these variables, the
original relationship we observed between elevated vancomy-
cin MIC and mortality persisted. Moreover, this relationship
still existed in patients with MSSA bacteraemia who were
treated with ﬂucloxacillin, strengthening our contention that
elevated vancomycin MIC is a marker rather than a root cause
TABLE 2. Univariable and multivariable logistic regression
analysis for associations with 30-day mortality (n = 410)
Variablea
Univariable
Multivariable
p value OR 95% CI p value
Age  70 years <0.001 3.73 2.14–6.51 <0.001
Elevated vancomycin MICb <0.001 2.59 1.49–4.51 0.001
Pitt score  4 <0.001 2.79 1.54–5.06 0.001
Sepsis syndrome <0.001 3.28 1.53–7.03 0.002
CCI 0.003 NS
ICU admission 0.010 NS
Active injecting drug use 0.012 NS
Hospital onset 0.020 NS
CCI, Charlson Comorbidity Index; NS, not signiﬁcant (p  0.05).
aAs discussed in Results section, variables that were signiﬁcant on univariable
analysis that were not considered for multivariable analysis were presence of a Do
not resuscitate order (direct effect on outcome due to treatment modiﬁcation),
APACHE II score  18 and SAPS II score (collinearity with age), heart disease and
malignancy (collinearity with CCI).
bElevated vancomycin MIC deﬁned as Etest >1.5 mg/L.
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of the increased mortality observed in patients with SAB
caused by isolates with high-normal vancomycin MIC.
We had excluded DNR orders when analysing possible
predictors of 30-day mortality in our multivariable analysis
because of the direct impact on mortality from treatment
modiﬁcations or cessation. When we included DNR orders in
an alternative multivariable logistic stepwise regression model,
elevated vancomycin MIC was the last variable to be eliminated
before the ﬁnal model was obtained. Although DNR orders
and elevated vancomycin MIC were both strongly associated
with 30-day mortality on univariable analysis, DNR orders
were more strongly correlated compared with elevated
vancomycin MIC and may potentially reﬂect a more compli-
cated group of adverse prognostic markers. Clinical variables
that have been previously associated with the use of DNR
orders (such as age, malignancy, increased illness severity
scores, residence in long-term care facilities [15,16]) are
similar nonetheless to those that were associated with
elevated vancomycin MIC. As patients with these character-
istics are more likely to have frequent healthcare attendances,
they may be exposed to S. aureus strains or clones adapted to
healthcare settings that have higher vancomycin MIC (espe-
cially as hospital-onset bacteraemia and MRSA were also
associated with elevated vancomycin MIC).
We hypothesize that elevated vancomycin MIC is a marker
of an unknown organism factor or host–pathogen interaction
that predicts mortality. Aguado et al. [17] recently reported a
similar ﬁnding with higher rates of complicated bacteraemia in
patients with MSSA bacteraemia if the isolates had elevated
vancomycin MIC. Multiple studies have highlighted an associ-
ation between bacterial factors such as genotype and other
potential virulence determinants and outcome in S. aureus
infections [18,19]. Bacterial genotype has been associated with
elevated vancomycin MIC [20] as well as risk of infective
endocarditis in MRSA bacteraemia [21]. Healthcare-adaptation
of S. aureus strains and successful clones (not merely limited to
MRSA) may be an important determinant, especially as there
may be cumulative exposure in the older population. We also
observed that non-survivors in our cohort had higher rates of
sepsis syndrome and disease severity scores at onset of
bacteraemia, probably reﬂecting a host–pathogen interaction
involving some of these determinants.
Limitations of this study include the retrospective collection
of the new clinical data that we included, and the absence of
detailed organism testing to attempt to identify a virulence
determinant in the laboratory that could explain the enhanced
virulence that we observe clinically. It is possible that our ﬁnal
multivariable model was affected by excluding co-dependent
variables; however, performance of post-hoc analysis that
substituted some of these variables (such as replacing age
 70 years with APACHE II score) did not alter the outcome
of the ﬁnal model.
We found that the association between elevated vancomy-
cin MIC and 30-day mortality in patients with SAB persisted
after adjustment for possible clinical confounders, including
patients who were not treated with vancomycin. We
hypothesize that host–organism interactions or exposure to
healthcare-adapted S. aureus strains may explain this associa-
tion. Additional studies are required to explore the
importance of subtle variations in virulence that appear to
be important determinants of mortality from S. aureus
bacteraemia.
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